Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year?

Group 1 - Solventum (SOLV) is one of 974 companies in the Medical group, which is currently ranked 7 within the Zacks Sector Rank [2] - Solventum has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook with a 6.1% increase in the consensus estimate for full-year earnings over the past quarter [3] - Year-to-date, Solventum has gained approximately 10.8%, outperforming the Medical sector, which has returned an average of -2.7% [4] Group 2 - Solventum is part of the Medical Services industry, which consists of 58 companies and is currently ranked 99 in the Zacks Industry Rank, with a year-to-date loss of about 2.6% [5] - ANIXA BIOSCIENCES INC (ANIX) is another Medical stock that has outperformed the sector with a return of 51.7% year-to-date and has a Zacks Rank of 2 (Buy) [4][5] - The Medical - Biomedical and Genetics industry, to which ANIX belongs, has a total of 485 stocks and is currently ranked 105, with a year-to-date increase of 2.8% [6]